Prototype development and preclinical immunogenicity analysis of a novel minimally invasive electroporation device

Gene Therapy

Volumn 18, Issue 3, 2011, Pages 258-265

  Broderick, K E ^a   Shen, X ^a   Soderholm, J ^a   Lin, F ^a   McCoy, J ^a   Khan, A S ^b   Yan, J ^c   Morrow, M P ^c   Patel, A ^d   Kobinger, G P ^d   Kemmerrer, S ^a   Weiner, D B ^c   Sardesai, N Y ^b  

^a Research and Development   (United States)

^b Building 18   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d PUBLIC HEALTH AGENCY OF CANADA   (Canada)

Author keywords

dermal; DNA vaccine; electroporation; macaque

Indexed keywords

DNA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; BACTERIOPHAGE; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTROLLED STUDY; DNA IMMUNIZATION; ELECTRIC POTENTIAL; ELECTRODE; ELECTROPORATION; ENZYME LINKED IMMUNOSPOT ASSAY; GENE TARGETING; GENETIC TRANSFECTION; GUINEA PIG; HUMAN; IMMUNOGENICITY; IN VIVO STUDY; INFLUENZA VIRUS A H1N1; INJECTION SITE; MACACA; MOUSE; NERVE CELL; NONHUMAN; PANDEMIC; PARAMETER; PLASMID; PRIORITY JOURNAL; SKIN CULTURE; T LYMPHOCYTE;

ANIMALS; ANTIGENS, VIRAL; ELECTRODES; ELECTROPORATION; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GUINEA PIGS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; TRANSFECTION; VACCINES, DNA;

ANIMALIA; CAVIA; MACACA;

EID: 79952490714     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2010.137     Document Type: Article

References (29)

1. Weiner DB. DNA vaccines: crossing a line in the sand introduction to special issue. Vaccine 2008; 26: 5073-5074.
2. Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15: 617-648, review. (Pubitemid 27169294)
3. Andre S, Seed B, Eberle J, Schraut W, Bültmann A, Haas J. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 1998; 72: 1497-1503. (Pubitemid 28116938)
4. Deml L, Bojak A, Steck S, Graf M, Wild J, Schirmbeck R et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol 2001; 75: 10991-11001. (Pubitemid 33031566)
5. Schneider R, Campbell M, Nasioulas G, Felber BK, Pavlakis GN. Inactivation of the human immunodeficiency virus type 1 inhibitory elements allows Rev-independent expression of Gag and Gag/protease and particle formation. J Virol 1997; 71: 4892-4903. (Pubitemid 27258156)
6. Muthumani K, Zhang D, Dayes NS, Hwang DS, Calarota SA, Choo AY et al. Novel engineered HIV-1 East African Clade-A gp160 plasmid construct induces strong humoral cell-mediated immune responses in vivo. Virology 2003; 314: 134-146. (Pubitemid 37153304)
7. Yang JS, Kim JJ, Hwang D, Choo AY, Dang K, Maguire H et al. Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999). J Infect Dis 2001; 184: 809-816. (Pubitemid 32881085)
8. Gao F, Weaver EA, Lu Z, Li Y, Liao HX, Ma B et al. Antigenicity immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein. J Virol 2005; 79: 1154-1163. (Pubitemid 40053898)
9. Yan J, Yoon H, Kumar S, Ramanathan MP, Corbitt N, Kutzler M et al. Enhanced cellular immune responses elicited by an engineered HIV-1 subtype B consensus-based envelope DNA vaccine. Mol Ther 2007; 15: 411-421. (Pubitemid 46111893)
10. Toebak MJ, Gibbs S, Bruynzeel DP, Scheper RJ, Rustemeyer T. Dendritic cells: biology of the skin. Contact Dermatitis 2009; 60: 2-20, review.
11. Tobin DJ. Biochemistry of human skin-our brain on the outside. Chem Soc Rev 2006; 35: 52-67, review. (Pubitemid 43485013)
12. Martinon F, Kaldma K, Sikut R, Culina S, Romain G, Tuomela M et al. Persistent immune responses induced by a human immunodeficiency virus DNA vaccine delivered in association with electroporation in the skin of nonhuman primates. Hum Gene Ther 2009; 20: 1291-1307.
13. Song JM, Kim YC, Lipatov AS, Pearton M, Davis CT, Yoo DG et al. Microneedle delivery of H5N1 influenza virus-like particles to the skin induces long-lasting B and T cell responses in mice. Clin Vaccine Immunol 2010; 17: 1381-1389.
14. Pertmer TM, Eisenbraun MD, McCabe D, Prayaga SK, Fuller DH, Haynes JR. Gene gun-based nucleic acid immunization: elicitation of humoral and cytotoxic T lymphocyte responses following epidermal delivery of nanogram quantities of DNA. Vaccine 1995; 13: 1427-1430.
15. Fuller DH, Murphey-Corb M, Clements J, Barnett S, Haynes JR. Induction of immunodeficiency virus-specific immune responses in rhesus monkeys following gene gun-mediated DNA vaccination. J Med Primatol 1996; 25: 236-241. (Pubitemid 126463685)
16. Braive A, Ljungberg K, Boberg A, Rollman E, Isaguliants M, Lundgren B. et al. Multigene/multisubtype HIV-1 vaccine induces potent cellular humoral immune responses by needle-free intradermal delivery. Mol Ther 2005; 12: 1197-1205. (Pubitemid 41723054)
17. Widera G, Austin M, Rabussay D, Goldbeck C, Barnett SW, Chen M et al. Increased DNA vaccine delivery immunogenicity by electroporation in vivo. J Immunol 2000; 164: 4635-4640. (Pubitemid 30238062)
18. Prud¢homme GJ, Draghia-Akli R, Wang Q. Plasmid-based gene therapy of diabetes mellitus. Gene Ther 2007; 14: 553-564. (Pubitemid 46444529)
19. Otten G, Schaefer M, Doe B, Liu H, Srivastava I, zur Megede J et al. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004; 22: 2489-2493. (Pubitemid 38757348)
20. Otten GR, Schaefer M, Doe B, Liu H, Megede JZ, Donnelly J et al. Potent immuno-genicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 2006; 24: 4503-4509. (Pubitemid 43776779)
21. Mathiesen I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999; 6: 508-514. (Pubitemid 29192659)
22. Hirao LA, Wu L, Khan AS, Satishchandran A, Draghia-Akli R, Weiner DB. Intradermal/ subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques. Vaccine 2008; 26: 440-448.
23. Rabussay DP, Nanda GS, Goldfarb PM. Enhancing the effectiveness of drug-based cancer therapy by electroporation (electropermeabilization). Technol Cancer Res Treat 2002; 1: 71-82. (Pubitemid 36553958)
24. Tjelle TE, Salte R, Mathiesen I, Kjeken R. A novel electroporation device for gene delivery in large animals and humans. Vaccine 2006; 24: 4667.
25. Draghia-Akli R, Khan AS, Brown PA, Pope MA, Wu L, Hirao L et al. Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine 2008; 26: 5230-5237.
26. Laddy DJ, Yan J, Khan AS, Andersen H, Cohn A, Greenhouse J et al. Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol 2009; 83: 4624-4630.
27. Laddy DJ, Yan J, Kutzler M, Kobasa D, Kobinger GP, Khan AS et al. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. PLoS One 2008; 3: e2517.
28. Gasparić M, Rubio I, Thönes N, Gissmann L, Müller M. Prophylactic DNA immunization against multiple papilloma virus types. Vaccine 2007; 25: 4540-4553. (Pubitemid 46734538)
29. Thönes N, Müller M. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology 2007; 369: 375-388. (Pubitemid 350087191)